Spondyloarthritis & psoriatic arthritis
Do DMARDs increase the risk of cancer recurrence in patients with spondyloarthritis, psoriatic arthritis and rheumatoid arthritis?
Main finding · Cancer recurrenceResult — go to the resultHazard ratio 2.79 95% CI 1.33–5.84Authors' conclusion
The risk of cancer recurrence associated with post-cancer immunosuppression appears largely driven by patients' age and comorbidities rather than the therapy itself. We found no evidence that initiating treatment within the standard 5-year safety window increases recurrence risk
Study context
- Population
- Patients with spondyloarthritis (SpA), psoriatic arthritis (PsA) or rheumatoid arthritis (RA) and concomitant invasive cancer (2015–2024)43 SpA, 35 PsA, 50 RA
- Participants
- 128 patients
- Exposure
- Post-cancer exposure to bDMARDs or JAKi vs no such exposure
- SpAn = 43
- PsAn = 35
- RAn = 50
- Outcome
- Cancer recurrence or progression
Methodological detailsconsecutive enrolment, time-dependent Cox proportional hazards models, sensitivity analyses adjusted for age, comorbidities and treatment history
- Consecutive enrolment
- Time-dependent Cox proportional hazards models
- Sensitivity analyses adjusted for age, comorbidities and treatment history
Main finding
Cancer recurrence
Hazard ratio
2.79
95% CI 1.33–5.84
bDMARDs or JAKivs Unexposed
HR 2.79 (95% CI 1.33–5.84)
As reported in the abstract
- Cancer recurrence or progression, whole cohort
- 24 (18.7%)
Observational data: associations, not effects.
Further findings
Timing of treatment initiation after cancer diagnosis (cut-offs 36, 48, 60, 72 months) and recurrence
- No significant association with recurrence risk
Original publication
Do DMARDs increase the risk of cancer recurrence in patients with spondyloarthritis, psoriatic arthritis and rheumatoid arthritis? Clin Exp Rheumatol. Published 22 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →